The Michael J. Fox Foundation Launches Target De-Risking Initiative for Parkinson’s Disease

Milan (Italy) – We are thrilled to share our active participation in a groundbreaking initiative launched by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This effort focuses on evaluating and de-risking druggable targets for Parkinson’s disease (PD), with the goal of accelerating therapeutic development.

As part of this initiative, we had the privilege of collaborating with leading drug development experts from academia, industry, and VC firms. Together, we contributed to establishing frameworks for target evaluation and identifying critical gaps to address. This collaborative approach is a testament to the power of partnerships in driving innovation for PD therapies.

Looking ahead, we are excited to see validation efforts for these targets in 2025 and to continue working with the broader PD research community to advance this important mission.

For more details about the MJFF Target Prioritization Initiative and its latest updates, visit: MJFF Target Prioritization Initiative and Golgi Neurosciences’ Linkedin Page